Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering [Yahoo! Finance]
How Monte Rosa's MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE's Risk-Reward Profile [Yahoo! Finance]
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences